The design and sample size of our study allowed us to not only evaluate molecular subtypes in relation to both overall as well as breast cancers specific subtypes, but also study the effect of dual versus single HER2-blockade in relation to molecular subtypes through interaction tests and subgroup analyses. This evidence concerns the gene ERBB2 and breast carcinoma.